Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04081337 · ClinicalTrials.gov registry record · Phase 1
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT04081337 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 55 participants.
The verdict
NCT04081337, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2022-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04081337
The ClinicalTrials.gov registry entry for NCT04081337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04081337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04081337 about?
NCT04081337 is a clinical study titled "A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide". This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
What is the current status of trial NCT04081337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2020-07-09. Estimated completion is 2022-05-26.
What interventions are being tested in trial NCT04081337?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT04081337?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.